Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Clinical Pharmacy and Pharmacology | JAMA – JAMA Network

by

  1. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss | Clinical Pharmacy and Pharmacology | JAMA JAMA Network
  2. Study finds popular weight loss drugs can lead to serious problems | 9 News Australia 9 News Australia
  3. Researchers link popular weight loss drugs to serious digestive problems for ‘hundreds of thousands’ worldwide CNN
  4. GLP-1 Agonists, Like Ozempic and Wegovy, Have Risk of Gut Issues: Study BioSpace
  5. GLP-1 Agonists Linked to Higher Risk for GI Complications Medscape
  6. View Full Coverage on Google News

Read original article here

Leave a Comment